Want to join the conversation?
$ABBV adjusted R&D was 15.5% of sales, reflecting funding action supporting the pipeline and the impact of both Stemcentrx transaction and the Boehringer Ingelheim collaboration. Adjusted SG&A was 22.2% of the sales in 2Q16, down 290 BPs from the prior year. Adjusted operating margin was 43.9% of sales, down 30 BPs relative to 2Q15.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)